Holen Sie sich die Stockscreener-App
256.42
0.37%
0.94
Handel nachbörslich:
257.94
1.52
+0.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$255.48
Offen:
$254.17
24-Stunden-Volumen:
4.24M
Relative Volume:
0.66
Marktkapitalisierung:
$453.12B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
126.48
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
-3.06%
1M Leistung:
+2.13%
6M Leistung:
+10.49%
1J Leistung:
+21.87%
1-Tages-Spanne:
$252.33
$258.24
1-Wochen-Bereich:
$252.33
$266.90
52-Wochen-Spanne:
$190.75
$267.47
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
256.42 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,156.73 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.85 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
147.76 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
152.06 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie (NYSE:ABBV) Large-Cap Healthcare Strategy Gains Attention - Kalkine Media
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market - Trefis
AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026 - Yahoo Finance
AbbVie Presents New Data Across Lung Cancer Pipeline At WCLC 2026 - marketscreener.com
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline - Investing News Network
AbbVie presents lung cancer data at WCLC 2026 conference By Investing.com - Investing.com Canada
AbbVie will present 90% lung cancer response data; the treatment remains investigational - Stock Titan
AbbVie Stock's Uncoupled Performance - Trefis
Jennison Associates LLC Trims Stake in AbbVie Inc. $ABBV - MarketBeat
Oppenheimer & Co. Inc. Acquires 5,934 Shares of AbbVie Inc. $ABBV - MarketBeat
Hodges Capital Management Inc. Has $4.94 Million Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead - AOL.com
Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie stock hits fresh 52-week high as earnings strength and guidance lift outlook - Ad-hoc-news.de
AbbVie Inc. $ABBV Shares Sold by D.A. Davidson & CO. - MarketBeat
Benjamin Edwards Inc. Reduces Position in AbbVie Inc. $ABBV - MarketBeat
GUBRA: Biotech revenue normalized post-AbbVie deal; CRO rebounded with 11% growth and profitability - TradingView
GUBRA: Revenue fell after last year's AbbVie deal, but clinical and CRO progress support long-term growth - TradingView
AbbVie (ABBV) Earnings Report: EPS Does Not Reach the Reported Estimate in the Current Update; Stock Move: The Stock Gains 2.72%Cost Structure Review - Vinanet
AbbVie Raises $9 Billion Debt to Fund Acquisition - The Globe and Mail
AbbVie (NYSE:ABBV) Shares Up 2.6%What's Next? - MarketBeat
Is AbbVie Stock About To Break Out Again? - Yahoo Finance
HARMONY ASSET MANAGEMENT LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Billionaire Ken Griffin Increased His Position in This Dividend King by 547% - Yahoo Finance
Munich Reinsurance Co Stock Corp in Munich Has $39.59 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 32,710 Shares - MarketBeat
AbbVie stock holds firm after Q2 revenue beat - Ad-hoc-news.de
Is AbbVie Inc (ABBV) Overvalued After 3.4% Rally? GF Value Says - GuruFocus
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
AbbVie (NYSE:ABBV) Trading Up 3.5%Still a Buy? - MarketBeat
Form 8K AbbVie Inc For: 18 August By Investing.com - Investing.com Nigeria
AbbVie completes $8.75B note offering to fund Apogee acquisition - TradingView
AbbVie (NYSE: ABBV) issues new senior notes with Apogee-linked redemption - Stock Titan
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Inc Stock (ABBV) Closed Up by 3.48% on Aug 18: Key Drivers Unveiled - TradingKey
Revance hires Janelle Wichmann as chief marketing officer of skincare unit - Fierce Pharma
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support - Investing News Network
AbbVie Inc. $ABBV Shares Sold by Capital Investment Advisory Services LLC - MarketBeat
AbbVie Inc. $ABBV Shares Acquired by ABN Amro Investment Solutions - MarketBeat
Abundance Wealth Counselors Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Wells Fargo raises Abbvie stock price target on HS drug potential - Investing.com Canada
Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? - AOL.com
Wells Fargo Adjusts Price Target on AbbVie to $300 From $295, Keeps Overweight Rating - marketscreener.com
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth With A 10.74% Potential Upside - DirectorsTalk Interviews
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? - AOL.com
AbbVie Inc. $ABBV Shares Bought by Exchange Traded Concepts LLC - MarketBeat
Bellecapital International Ltd. Acquires 8,728 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Bought by Confluence Wealth Services Inc. - MarketBeat
Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year - AOL.com
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbvie Inc-Aktie (ABBV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER |
Aug 14 '26 |
Sale |
250.00 |
32,710 |
8,177,500 |
74,430 |
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):